Exploring the Sinus Microbiome

The Cervin group is investigating the microbiome of the nose, sinus and throat of individuals with healthy sinuses and chronic sinus infections to gather new information on the sinus microbiome. Through this work we have identified a number of friendly bacteria (commensals) from healthy individuals that have the ability to reduce the growth of bacterial strains associated with chronic sinus infections in vitro.

Testing a Microbiome Therapy for Chronic Rhinosinusitis

Through a collaboration with Winclove Probiotics and ENT Technologies the Cervin Group is developing a microbiome therapy nasal spray to treat chronic rhinosinusisits. Preparations are currently underway to test this treatment in humans. 

A Microbiome Therapy to Prevent Otitis Media in Aboriginal and Torres Straight Island Children

The Aboriginal and Torres Strait Island population have some of the highest rates of Otitis Media in the world. In collaboration with The Deadly Ears Program the Cervin Group has started a research program exploring the normal bacterial flora in the upper airway in the indigenous population and how it contributes to maintaining health. The aim of this study is to prevent Otitis Media in Aboriginal and Torres Strait Islander children by supplementing the airway with a microbiome therapy. 

For further information download the study brochure.

Reducing troublesome nasal tissue with Radiofrequency Ablation in an Australian hospital setting

Radiofrequency ablation is a well-established, effective treatment for reducing troublesome nasal tissue that is offered to patients as an alternative to surgery in the United States and the United kingdom, however, this treatment is rarely used in Australia. This study aims to assess the radiofrequency ablation (RFA) treatment in an Australian hospital setting.